(Q38113093)

29 August 2017

title

Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin (English)

1 reference

29 August 2017

1

George Grunberger

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

29 August 2017

published in

Postgraduate Medicine

1 reference

29 August 2017

volume

125

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

79-90

1 reference

Standards of medical care in diabetes--2012

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Frequency of hypoglycemia and its significance in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

21 January 2018

Sitagliptin: a review

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Pharmacokinetics of linagliptin in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Special considerations for treatment of type 2 diabetes mellitus in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Pharmacologic management of the older patient with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Pharmacogenetics in drug regulation: promise, potential and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Natural substrates of dipeptidyl peptidase IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Peptide substrates of dipeptidyl peptidases

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2663

21 January 2018

Identifiers

DOI

10.3810/PGM.2013.05.2663

1 reference

29 August 2017

1 reference